Literature DB >> 9890267

Establishment of an adrenocortical carcinoma xenograft with normotensive hyperaldosteronism in vivo.

H Yamazaki1, Y Abe, Y Katoh, N Sawa, Y Ohnishi, Y Tanaka, H Sasano, Y Oshika, T Tokunaga, H Kijima, N Tamaoki, M Nakamura, Y Ueyama.   

Abstract

We established a xenograft line of human adrenocortical carcinoma (ADR-1), and analyzed the hyperaldosteronism induced by the xenograft in vivo. Adrenocortical carcinoma specimens from a 25-year-old woman were subcutaneously inoculated into nude mice (BALB/c-nu/nu) followed by serial passages in vivo. ADR-1 retained the histopathological features (trabecular and sinusoid nests) seen in the primary carcinoma. The patient showed hyperaldosteronism (serum aldosterone >4000 pg/ml) and hypokalemia (serum K 2.1 mEq/l), but did not show hypertension. The nude rat (F344-rnu/rnu) bearing ADR-1 showed hyperaldosteronism (serum aldosterone 3320+/-1420 pg/ml; control 191+/-130 pg/ml) and hypokalemia (serum K 3.4+/-0.4 mEq/l; control 5.2+/-1.0 mEq/l) in vivo, and hypertension was not obvious. ADR-1 was shown immunohistochemically to retain production of human-specific corticosteroid synthetase. The xenograft ADR-1 will be useful to elucidate the regulatory mechanism of normotensive hyperaldosteronism.

Entities:  

Mesh:

Year:  1998        PMID: 9890267     DOI: 10.1111/j.1699-0463.1998.tb00258.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

1.  Aldosterone-producing adrenocortical carcinoma without hypertension.

Authors:  Min Soo Song; Sung Woo Seo; Sang Byung Bae; Yeo Joo Kim; Sang Jin Kim
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.